[September 20, 2017] |
|
Viceroy Research Believes MiMedx's Employment of Kickback & Bribery Scheme Inducers Makes It Uninvestable
Viceroy Research (Viceroy) today released its research and analysis of MiMedx
Group Inc. (NASDAQ: MDXG). MiMedx is a company primarily engaged in
the manufacture and sale of amniotic products for the medical sector,
including the United States Department of Veterans Affairs.
Viceroy Research uncover substantial previously-unreported
data evidencing an incestuous hiring policy from a kickback
& bribery company scheme, a possible SEC (News - Alert)
enforcement investigation, and indications of channel
stuffing.
While MiMedx outward appearance is one of dynamic and successful
organization, the reality is much different and raises serious concerns.
For the full Viceroy report on MiMedx, click here: www.viceroyresearch.org
Follow Viceroy on Twitter (News - Alert): @ViceroyResearch
Through extensive research Viceroy has uncovered startling issues:
-
Sean McCormack, the company's "Director of New Market Initiatives,"
allegedly directed a kickback and bribery inducement scheme at
Advanced BioHealing, which resulted in the largest False Claims
act settlement ever (January 20171 $350M). At least 54
Advanced BioHealing alumnus have been identified by Viceroy within
MiMedx's sales force including at least 15 in senior/principle
employment positions.
-
The SEC's response to a FOIA request suggests MiMedx may already
have an undisclosed SEC investigtion. Viceroy believes this puts
the company at serious risk of losing its ability to supply government
agencies, which makes up a substantial portion of its income.
-
MiMedx's System for Award Management (SAM) government compliance
certification was filed by an employee that left 3 months before the
filing date. Viceroy believes material disclosures were absent
regarding employees previously associated with illegally inducing
sales.
-
A large number of MiMedx's senior sales staff were previously
employed by Advanced BioHealing, and their presence seems to be
something MiMedx would prefer hidden.
-
MiMedx employees/ex-employees have set up resale businesses for MiMedx
products under their own names without any apparent disclosure.
Viceroy calls in to question the quality of sales to such businesses
and the reasoning behind the disguise.
-
Whistleblowers claimed MiMedx conducted channel-stuffing operations,
and while these claims were withdrawn, Viceroy highlights key factors
in those claims that raise serious concerns.
-
MiMedx's rapid acquisition and divestment of Stability Biologics
raises serious questions about MiMedx financial literacy. It
appears MiMedx bought a business engaged in channel- stuffing.
-
When its longtime auditors began finding material weaknesses in the
company's internal controls, MiMedx's response was to change
auditors.
1 https://www.justice.gov/opa/pr/shire-plc-subsidiaries-pay-350-million-settle-false-claims-act-allegations
About Viceroy Research
Viceroy is an investigative financial research group. As global markets
become more opaque and complex, and traditional gatekeepers and
safeguards often compromised, investors and shareholders are at greater
risk than ever of being misled or uninformed by public companies and
their promoters and sponsors. Our mission is to sift fact from fiction
and encourage greater management accountability through transparency in
reporting and disclosure by public companies and overall improve the
quality of global capital markets. Viceroy's analysts utilize experience
from diverse backgrounds including finance, engineering, forensic
accounting, and law. Our research is further developed and vetted
through an extensive consultant network of industry specialists. Visit: www.viceroyresearch.org
View source version on businesswire.com: http://www.businesswire.com/news/home/20170920005861/en/
[ Back To TMCnet.com's Homepage ]
|